Anti-cyclic citrullinated peptide antibody titers decrease in rheumatoid arthritis patients treated with tocilizumab : A pilot study

Noguchi, Atsushi; Yasuda, Shinsuke; Hisada, Ryo; Kato, Masaru; Oku, Kenji; Bohgaki, Toshiyuki; Suzuki, Miho; Matsumoto, Yoshihiro; Atsumi, Tatsuya

Anti-cyclic citrullinated peptide antibody titers decrease in rheumatoid arthritis patients treated with tocilizumab : A pilot study

Noguchi, Atsushi; Yasuda, Shinsuke; Hisada, Ryo et al.

Modern rheumatology, 2020, 30(2), 276-281

Permalink : https://hdl.handle.net/2115/80540

このアイテムのアクセス数:569件（2026-08-13 02:04 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数
Mod Rheumatol_30_276	pdf	456 KB	740
Suppl. Fig 1	tif	2.98 MB	102
Suppl. Fig 2	tif	2.95 MB	83

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/80540
タイトル	Anti-cyclic citrullinated peptide antibody titers decrease in rheumatoid arthritis patients treated with tocilizumab : A pilot study
著者	Noguchi, Atsushi ; Yasuda, Shinsuke ; Hisada, Ryo ; Kato, Masaru ; Oku, Kenji ; Bohgaki, Toshiyuki ; Suzuki, Miho ; Matsumoto, Yoshihiro ; Atsumi, Tatsuya
著者名 Noguchi, Atsushi
e-Rad_Researcher 00374231 著者名 Yasuda, Shinsuke
著者名 Hisada, Ryo
e-Rad_Researcher 10755896 著者名 Kato, Masaru
e-Rad_Researcher 70544295 著者名 Oku, Kenji
e-Rad_Researcher 50431367 著者名 Bohgaki, Toshiyuki
著者名 Suzuki, Miho
著者名 Matsumoto, Yoshihiro
e-Rad_Researcher 20301905 著者名 Atsumi, Tatsuya
言語	英語
キーワード	Anti-cyclic citrullinated peptide antibody
	B-cell subpopulation
	rheumatoid arthritis
	tocilizumab
発行日	2020-03-03
出版者	Taylor & Francis
収録物名	Modern rheumatology
巻(号)	30(2)
ページ	276-281
抄録	Objectives: To analyze the effects of tocilizumab on peripheral B-cell subpopulation and its ability to produce anti-cyclic citrullinated peptide (CCP) antibody in patients with rheumatoid arthritis (RA). Methods: Thirteen consecutive RA patients initiated with tocilizumab were enrolled in our prospective study. Anti-CCP antibody titers and clinical parameters were evaluated during treatment. Peripheral blood B-cell subsets were analyzed using flow cytometry according to the Human Immunology Project. Results: Disease activity was significantly improved and anti-CCP antibody titers significantly decreased at week 24 compared to baseline. The percentages of post-switch memory B cells in CD19+ cells transiently increased at week 12, but there was no significant difference in any of the investigated B-cell subpopulations at week 24 compared to baseline. The ratios of post-switch memory to naive B cells (post-switch/naive) correlated negatively with anti-CCP antibody titers regardless of the time-points. Conclusion: Our study indicated that tocilizumab has a potential to reduce anti-CCP antibody production presumably by affecting post-switch/naive ratio, and that anti-CCP antibody titers reflect B-cell distribution/subpopulation. As anti-CCP antibodies are produced in lymph nodes or ectopic lymphoid structures in synovial tissues, not in circulation, transient increment of post-switch memory B cells after tocilizumab treatment may reflect the altered balance of B-cell distribution between circulation and arthritic joints, resulting in suppressed production of anti-CCP antibody in situ.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	This is an Accepted Manuscript of an article published by Taylor & Francis in Modern rheumatology on 3 Mar 2020, available online: http://www.tandfonline.com/10.1080/14397595.2019.1583784.
PISSN	1439-7595
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1080/14397595.2019.1583784